amikacin has been researched along with tazobactam in 55 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 10 (18.18) | 18.2507 |
2000's | 21 (38.18) | 29.6817 |
2010's | 15 (27.27) | 24.3611 |
2020's | 9 (16.36) | 2.80 |
Authors | Studies |
---|---|
Cho, SH; Franzblau, SG; Hwang, CH; Pauli, GF; Wan, B; Warit, S | 1 |
Cauda, R; D'Inzeo, T; De Pascale, G; Fadda, G; Fiori, B; Leone, F; Rossi, M; Sali, M; Sanguinetti, M; Spanu, T; Trecarichi, EM; Tumbarello, M | 1 |
Andlovic, A; Jeverica, S; Karisik, E; Koren, S; Krizan-Hergouth, V; Livermore, DM; Mesko Meglic, K; Müller-Premru, M; Palepou, MF; Pike, R; Seme, K; Woodford, N | 1 |
Kirikae, T; Kitao, T; Miyoshi-Akiyama, T | 1 |
Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
Chamard-Neuwirth, C; Cordin, X; Duez, JM; Kazmierczak, A; Pechinot, A; Siebor, E | 2 |
Cony-Makhoul, P; Fière, D; Guy, H; Herbrecht, R; Marie, JP; Milpied, N; Pico, JL; Plantier, I; Vekhoff, A | 1 |
Sanders, CV | 1 |
Gentile, G; Girmenia, C; Martino, P; Meloni, G; Micozzi, A; Nucci, M; Venditti, M | 1 |
Bayle, C; Bourhis, JH; Cartron, J; Gautier, E; Pico, JL; Tchernia, G | 1 |
Andremont, A; Guy, H; Marie, JP; Pico, JL; Richet, H; Vekhoff, A | 1 |
Böhme, C; Hess, U; Rey, K; Senn, HJ | 1 |
Babini, GS; Bates, J; Livermore, DM; Palepou, MF; Woodford, N | 1 |
Caballero, D; Encinas, MP; García-Sanz, R; Gutiérrez, N; Hurlé, AD; Morín, LS; Vázquez, L; Vilches, P | 1 |
Carbon, C; Carlet, J; Dupont, H | 1 |
Aznar, E; Climent, MA; Máiquez, J; Palau, J; Picón, I | 1 |
Burgess, DS; Hastings, RW | 1 |
Cohen, J | 1 |
O'Connell, M; Petros, AJ; Roberts, C; van Saene, HK; Wade, P | 1 |
Abi-Said, D; Bivins, C; Hachem, R; Hanna, H; Huaringa, A; Raad, I; Sukumaran, A; Thornby, J; Walsh, G; Whimbey, E | 1 |
Minami, S; Takahata, M; Yamada, H | 1 |
Batlle, M; Benlloch, L; Capote, FJ; Gutiérrez, M; Jarque, I; Julià, A; Lahuerta, JJ; Larrea, L; López, J; Palau, J; Pérez, C; Ramos, F; Rovira, M; Sanz, MA; Vázquez, L | 1 |
Aksoylar, S; Cetingül, N; Kansoy, S; Kantar, M; Karapinar, D; Kavakli, K | 1 |
Jakoniuk, P; Leszczyńska, K; Sacha, PT; Wieczorek, P; Zalewska, M | 1 |
Ashkenazi, S; Bishara, J; Lev, B; Levy, I; Livne, G; Ofir, O; Pitlik, S; Samra, Z | 1 |
Bermúdez, A; Besalduch, J; Nocea, G; Pascual, MJ; Rovira, M; Sanz, MA; Sanz-Rodríguez, C | 1 |
Pang, XY; Tian, BW; Yang, YJ | 1 |
Aydogdu, I; Ersoy, Y; Kaya, E; Kuku, I; Serefhanoglu, K; Serefhanoglu, S | 1 |
Hashikita, G; Kawakami, S; Kobayashi, S; Maesaki, S; Nagasawa, M; Okabe, T; Sasaki, K; Shibuya, S; Suzuki, N; Takayama, S; Uchida, T; Watanabe, M; Yamaguchi, T | 1 |
Albertí, S; Juan, C; Mulet, X; Oliver, A; Pérez, JL; Zamorano, L | 1 |
Kılıç, SC; Sarper, N; Zengin, E | 1 |
Blahut, L; Hricová, K; Kolár, M; Neiser, J; Urbánek, K; Uvízl, R; Vojtová, V | 1 |
Bernusset, S; Cattoen, C; Cuzon, G; Naas, T; Nordmann, P | 1 |
Celebi, S; Demirkaya, M; Hacımustafaoglu, M; Sevinir, B | 1 |
Aghazadeh, M; Hojabri, T; Hojabri, Z; Mahdian, R; Nahaei, MR; Pajand, O; Pirzadeh, T; Rahmati, M | 1 |
Banerjee, R; Boyce, TG; Cunningham, SA; Hasassri, ME; Jeraldo, PR; Kaye, KS; Norgan, AP; Patel, R; Pogue, JM; Weissman, SJ | 1 |
Choudhary, S; Makwana, M; Soni, JP; Tripathi, N | 1 |
Abdel-Haq, N; Ang, JY; Nicolau, DP; Satlin, MJ; Thabit, AK; van Duin, D; Zhu, F | 1 |
Alp, E; Çetin, M; Elmali, F; Kaynar, L; Kürkçüoglu, CA; Metan, G; Yozgat, N | 1 |
Chesnel, L; Howland, K; Jacqueline, C | 1 |
Ali, I; Shabbir, M | 1 |
Castanheira, M; Flamm, RK; Pfaller, MA; Shortridge, D | 1 |
Attwood, M; Bowker, KE; MacGowan, AP; Noel, AR | 1 |
Fernández Esgueva, M; Ferrer Cerón, I; García-Lechuz Moya, JM; López-Calleja, AI; Morilla Morales, E; Nuñez Medina, R; Rezusta López, A; Sahagún Pareja, J; Viñuelas Bayon, J | 1 |
Charoenkwan, P; Choeyprasert, W; Fanhchaksai, K; Kamonrattana, R; Natesirinilkul, R; Sathitsamitphong, L | 1 |
Alaghehbandan, R; Alinejad, F; Azimi, L; Lari, AR; Tahbaz, SV | 1 |
Adamou, P; Antoniadou, A; Damala, M; Deliolanis, I; Fountoulis, K; Galani, I; Galani, L; Giamarellou, H; Karaiskos, I; Karantani, I; Kirikou, H; Kodonaki, A; Maraki, S; Markopoulou, M; Papadogeorgaki, E; Papoutsaki, V; Petinaki, E; Prifti, E; Souli, M; Tsiplakou, S; Vagiakou, E | 1 |
Carvalhaes, CG; Castanheira, M; Doyle, TB; Sader, HS; Streit, JM | 1 |
Bragantini, D; Carrara, E; Cattaneo, P; Chiamenti, M; Ellis, S; Franceschi, F; Giske, CG; Lodise, T; Menchinelli, G; Piddock, LJV; Righi, E; Sanguinetti, M; Savoldi, A; Scudeller, L; Tacconelli, E | 1 |
Güler, N; Süleyman, A; Tamay, Z | 1 |
Caljon, B; Crombé, F; De Geyter, D; Demuyser, T; Janssen, T; Muyldermans, A; Piérard, D; Seyler, L; Vanstokstraeten, R; Wybo, I | 1 |
Jia, P; Xu, Y; Yang, Q; Yu, W; Zhang, H; Zhu, Y | 1 |
Cao, Y; Liu, C; Ren, H; Shang, Z; Wang, R; Xie, L; Yang, Y; Zhang, J | 1 |
Chen, WT; DeRyke, CA; Karlowsky, JA; Lob, SH; Motyl, MR; Sahm, DF; Siddiqui, F; Young, K | 1 |
1 review(s) available for amikacin and tazobactam
Article | Year |
---|---|
Systematic review and meta-analysis of in vitro efficacy of antibiotic combination therapy against carbapenem-resistant Gram-negative bacilli.
Topics: Amikacin; Anti-Bacterial Agents; Azabicyclo Compounds; Carbapenems; Ceftazidime; Cephalosporins; Colistin; Drug Combinations; Drug Resistance, Bacterial; Drug Synergism; Drug Therapy, Combination; Fosfomycin; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Imipenem; In Vitro Techniques; Microbial Sensitivity Tests; Polymyxins; Rifampin; Tazobactam; Tobramycin | 2021 |
15 trial(s) available for amikacin and tazobactam
Article | Year |
---|---|
[Piperacilline/tazobactam combination+amikacin versus ceftazidime+amikacin in patients with neutropenia and fever. An open multicenter study. Groupe d'étude des Aplasies Fébriles].
Topics: Adult; Aged; Amikacin; beta-Lactamase Inhibitors; Ceftazidime; Drug Therapy, Combination; Fever; Humans; Middle Aged; Neutropenia; Penicillanic Acid; Piperacillin; Tazobactam | 1995 |
Piperacillin/tazobactam in the treatment of community-acquired and nosocomial respiratory tract infections: a review.
Topics: Adult; Aged; Amikacin; beta-Lactamase Inhibitors; Community-Acquired Infections; Cross Infection; Drug Combinations; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Respiratory Tract Infections; Tazobactam | 1994 |
Piperacillin/tazobactam/amikacin versus piperacillin/amikacin/teicoplanin in the empirical treatment of neutropenic patients.
Topics: Adolescent; Adult; Aged; Amikacin; Bacteremia; Bacteria; Bacterial Infections; Drug Therapy, Combination; Female; Fever; Humans; Male; Middle Aged; Neutropenia; Penicillanic Acid; Piperacillin; Prospective Studies; Tazobactam; Teicoplanin | 1993 |
Neutropenic infections: a review of the French Febrile Aplasia Study Group trials in 608 febrile neutropenic patients.
Topics: Amikacin; Anti-Bacterial Agents; Ceftazidime; Cephalosporins; Ciprofloxacin; Drug Therapy, Combination; Fever; Hematologic Neoplasms; Humans; Multivariate Analysis; Neutropenia; Opportunistic Infections; Penicillanic Acid; Piperacillin; Tazobactam; Vancomycin | 1998 |
Monotherapy with piperacillin/tazobactam versus combination therapy with ceftazidime plus amikacin as an empiric therapy for fever in neutropenic cancer patients.
Topics: Adolescent; Adult; Aged; Amikacin; Analysis of Variance; Anti-Bacterial Agents; Ceftazidime; Chi-Square Distribution; Drug Therapy, Combination; Enzyme Inhibitors; Female; Fever; Humans; Male; Middle Aged; Neoplasms; Neutropenia; Penicillanic Acid; Piperacillin; Prognosis; Prospective Studies; Tazobactam; Treatment Failure; Treatment Outcome | 1998 |
Randomized prospective study comparing cost-effectiveness of teicoplanin and vancomycin as second-line empiric therapy for infection in neutropenic patients.
Topics: Amikacin; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Blood Chemical Analysis; Cost-Benefit Analysis; Drug Costs; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Hematologic Neoplasms; Humans; Male; Middle Aged; Neutropenia; Penicillanic Acid; Piperacillin; Prospective Studies; Safety; Tazobactam; Teicoplanin; Treatment Failure; Vancomycin | 1999 |
Monotherapy with a broad-spectrum beta-lactam is as effective as its combination with an aminoglycoside in treatment of severe generalized peritonitis: a multicenter randomized controlled trial. The Severe Generalized Peritonitis Study Group.
Topics: Adolescent; Adult; Amikacin; Anti-Bacterial Agents; Drug Therapy, Combination; Enzyme Inhibitors; Female; Humans; Male; Middle Aged; Penicillanic Acid; Penicillins; Peritonitis; Piperacillin; Tazobactam; Treatment Outcome | 2000 |
Treatment of nosocomial postoperative pneumonia in cancer patients: a prospective randomized study.
Topics: Aged; Amikacin; Aztreonam; Chi-Square Distribution; Clindamycin; Cross Infection; Drug Therapy, Combination; Humans; Middle Aged; Neoplasms; Opportunistic Infections; Penicillanic Acid; Piperacillin; Pneumonia, Bacterial; Postoperative Complications; Prognosis; Prospective Studies; Tazobactam | 2001 |
Cefepime plus amikacin versus piperacillin-tazobactam plus amikacin for initial antibiotic therapy in haematology patients with febrile neutropenia: results of an open, randomized, multicentre trial.
Topics: Adult; Amikacin; Anti-Bacterial Agents; Cefepime; Cephalosporins; Drug Therapy, Combination; Female; Fever; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Neutropenia; Penicillanic Acid; Piperacillin; Tazobactam; Treatment Outcome | 2002 |
Meropenem plus amikacin versus piperacillin-tazobactam plus netilmicin as empiric therapy for high-risk febrile neutropenia in children.
Topics: Amikacin; Anti-Bacterial Agents; Drug Therapy, Combination; Fever; Fungi; Gram-Negative Bacteria; Gram-Positive Bacteria; Hematologic Neoplasms; Humans; Infections; Meropenem; Neoplasms; Netilmicin; Neutropenia; Penicillanic Acid; Piperacillin; Tazobactam; Thienamycins | 2004 |
Imipenem/cilastatin versus piperacillin/tazobactam plus amikacin for empirical therapy in febrile neutropenic patients: results of the COSTINE study.
Topics: Adult; Amikacin; Anti-Bacterial Agents; Cilastatin; Cost-Benefit Analysis; Drug Therapy, Combination; Enzyme Inhibitors; Female; Fever; Hematopoietic Stem Cell Transplantation; Humans; Imipenem; Male; Middle Aged; Neoplasms; Neutropenia; Penicillanic Acid; Piperacillin; Prospective Studies; Protease Inhibitors; Spain; Tazobactam; Treatment Outcome | 2005 |
Clinical experience with three combination regimens for the treatment of high-risk febrile neutropenia.
Topics: Adolescent; Adult; Aged; Amikacin; Anti-Bacterial Agents; Ceftazidime; Drug Therapy, Combination; Female; Fever; Humans; Immunocompromised Host; Male; Meropenem; Middle Aged; Neutropenia; Penicillanic Acid; Piperacillin; Prospective Studies; Risk Assessment; Risk Factors; Tazobactam; Thienamycins | 2006 |
Piperacillin/tazobactam monotherapy versus piperacillin/tazobactam plus amikacin as initial empirical therapy for febrile neutropenia in children with acute leukemia.
Topics: Acute Disease; Adolescent; Amikacin; Anti-Bacterial Agents; Child; Child, Preschool; Female; Humans; Leukemia; Male; Neutropenia; Penicillanic Acid; Piperacillin; Tazobactam; Treatment Outcome; Young Adult | 2011 |
Randomized comparison of piperacillin-tazobactam plus amikacin versus cefoperazone-sulbactam plus amikacin for management of febrile neutropenia in children with lymphoma and solid tumors.
Topics: Adolescent; Amikacin; Anti-Bacterial Agents; Cefoperazone; Child; Child, Preschool; Drug Therapy, Combination; Female; Humans; Infant; Lymphoma, Non-Hodgkin; Male; Neutropenia; Penicillanic Acid; Piperacillin; Prospective Studies; Sulbactam; Tazobactam | 2013 |
A Randomized, Open-Labeled, Prospective Controlled Study to Assess the Efficacy of Frontline Empirical Intravenous Piperacillin/Tazobactam Monotherapy in Comparison with Ceftazidime Plus Amikacin for Febrile Neutropenia in Pediatric Oncology Patients.
Topics: Administration, Intravenous; Amikacin; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Ceftazidime; Child; Child, Preschool; Drug Therapy, Combination; Febrile Neutropenia; Female; Follow-Up Studies; Humans; Male; Neoplasms; Piperacillin; Prospective Studies; Retrospective Studies; Tazobactam; Treatment Outcome | 2019 |
39 other study(ies) available for amikacin and tazobactam
Article | Year |
---|---|
Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis.
Topics: Anti-Bacterial Agents; Antitubercular Agents; DNA, Bacterial; Drug Evaluation, Preclinical; Mycobacterium tuberculosis; Oxygen | 2007 |
Bloodstream infections caused by extended-spectrum-beta-lactamase- producing Escherichia coli: risk factors for inadequate initial antimicrobial therapy.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; beta-Lactamases; Drug Resistance, Multiple, Bacterial; Escherichia coli; Escherichia coli Infections; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Multivariate Analysis; Risk Factors; Treatment Failure | 2008 |
Nationwide survey of CTX-M-type extended-spectrum beta-lactamases among Klebsiella pneumoniae isolates in Slovenian hospitals.
Topics: Anti-Bacterial Agents; beta-Lactamases; Electrophoresis, Gel, Pulsed-Field; Genes, Bacterial; Hospitals; Klebsiella pneumoniae; Microbial Sensitivity Tests; Slovenia | 2009 |
AAC(6')-Iaf, a novel aminoglycoside 6'-N-acetyltransferase from multidrug-resistant Pseudomonas aeruginosa clinical isolates.
Topics: Acetylation; Acetyltransferases; Aminoglycosides; Drug Resistance, Multiple, Bacterial; Electrophoresis, Gel, Pulsed-Field; Humans; Integrons; Microbial Sensitivity Tests; Pseudomonas aeruginosa | 2009 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
[In vitro antibacterial activity of piperacillin-tazobactam in combination with netilmicin or amikacin against Enterobacteriaceae resistant to amoxicillin].
Topics: Amikacin; Amoxicillin; beta-Lactamase Inhibitors; Dose-Response Relationship, Drug; Drug Resistance, Microbial; Drug Synergism; Drug Therapy, Combination; Enterobacteriaceae; Enzyme Inhibitors; In Vitro Techniques; Netilmicin; Penicillanic Acid; Piperacillin; Tazobactam | 1995 |
Parvovirus B19 associated neutropenia. Treatment with Rh G-CSF.
Topics: Adenocarcinoma; Adult; Amikacin; Colonic Neoplasms; DNA, Viral; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Injections, Intravenous; Liver Neoplasms; Neutropenia; Parvoviridae Infections; Parvovirus B19, Human; Pefloxacin; Penicillanic Acid; Piperacillin; Recombinant Proteins; Tazobactam | 1997 |
Carbapenemase-producing Pseudomonas aeruginosa in UK.
Topics: Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Ceftazidime; Ciprofloxacin; Drug Resistance, Microbial; Enzyme Inhibitors; Gentamicins; Humans; Imipenem; Meropenem; Metalloproteins; Penicillanic Acid; Penicillins; Piperacillin; Pseudomonas aeruginosa; Tazobactam; Thienamycins; United Kingdom | 1998 |
[A three-dimensional model for in vitro study of the association of three antibiotics. Application to the activity of piperacillin, tazobactam and amikacin against five strains of enterobacteria as a function of their phenotype of beta-lactam resistance].
Topics: Amikacin; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamase Inhibitors; Drug Therapy, Combination; Enterobacteriaceae; Enzyme Inhibitors; Microbial Sensitivity Tests; Models, Biological; Penicillanic Acid; Penicillins; Phenotype; Piperacillin; Tazobactam | 1998 |
[Cost of antibiotic therapy in neutropenic patients undergoing peripheral blood stem cell transplantation for breast cancer].
Topics: Amikacin; Antineoplastic Agents; Breast Neoplasms; Drug Costs; Drug Therapy, Combination; Female; Fever; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Hematopoietic Stem Cell Transplantation; Hospital Costs; Humans; Neutropenia; Penicillanic Acid; Piperacillin; Spain; Tazobactam; Teicoplanin; Transplantation Conditioning; Treatment Failure; Treatment Outcome; Vancomycin | 2000 |
Activity of piperacillin/tazobactam in combination with amikacin, ciprofloxacin, and trovafloxacin against Pseudomonas aeruginosa by time-kill.
Topics: Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; Chi-Square Distribution; Ciprofloxacin; Colony Count, Microbial; Drug Resistance, Microbial; Drug Synergism; Drug Therapy, Combination; Enzyme Inhibitors; Fluoroquinolones; Humans; Naphthyridines; Penicillanic Acid; Penicillins; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2000 |
Combination antibiotic therapy for severe peritonitis.
Topics: Amikacin; Anti-Bacterial Agents; Drug Therapy, Combination; Enzyme Inhibitors; Humans; Penicillanic Acid; Penicillins; Peritonitis; Polypharmacy; Tazobactam | 2000 |
Systemic antibiotics fail to clear multidrug-resistant Klebsiella from a pediatric ICU.
Topics: Amikacin; beta-Lactamase Inhibitors; Cohort Studies; Cross Infection; Disease Outbreaks; Drug Resistance, Multiple; Drug Therapy, Combination; Female; Humans; Infant; Intensive Care Units, Pediatric; Klebsiella; Klebsiella Infections; Male; Penicillanic Acid; Piperacillin; Prospective Studies; Tazobactam | 2001 |
[In vitro interaction of tazobactam/piperacillin combined with aminoglycosides against Pseudomonas aeruginosa, Klebsiella pneumoniae, Escherichia coli AND Staphylococcus aureus].
Topics: Amikacin; Anti-Bacterial Agents; Drug Antagonism; Drug Combinations; Drug Resistance, Bacterial; Drug Synergism; Enzyme Inhibitors; Escherichia coli; Gentamicins; Microbial Sensitivity Tests; Penicillanic Acid; Penicillins; Piperacillin; Pseudomonas aeruginosa; Staphylococcus aureus; Tazobactam | 2002 |
[Antibiotic susceptibility and occurrence of ESBL in Pseudomonas aeruginosa strains isolated from different clinical specimens].
Topics: Amikacin; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; Cefotaxime; Ceftazidime; Ciprofloxacin; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Pseudomonas aeruginosa; Tazobactam; Thienamycins; Ticarcillin | 2004 |
Antibacterial susceptibility of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli.
Topics: Adult; Amikacin; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; beta-Lactamases; Child; Ciprofloxacin; Clavulanic Acid; Drug Resistance, Bacterial; Enzyme Inhibitors; Escherichia coli; Humans; In Vitro Techniques; Israel; Klebsiella pneumoniae; Microbial Sensitivity Tests; Odds Ratio; Penicillanic Acid; Piperacillin; Prevalence; Tazobactam | 2005 |
[Dynamic analysis of drug resistance of Pseudomonas aeruginosa in laboratory and clinical two-drug regimen].
Topics: Amikacin; Ciprofloxacin; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Sulbactam; Tazobactam | 2005 |
[The combination effects of antibacterial agents against clinical isolated multiple-drug resistant Pseudomonas aeruginosa].
Topics: Amikacin; Anti-Bacterial Agents; Aztreonam; Cefepime; Cefoperazone; Cephalosporins; Ciprofloxacin; Drug Combinations; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Fluoroquinolones; Humans; Meropenem; Microbial Sensitivity Tests; Oxazines; Penicillanic Acid; Piperacillin; Pseudomonas aeruginosa; Sulbactam; Tazobactam; Thienamycins | 2006 |
Detection of the novel extended-spectrum beta-lactamase OXA-161 from a plasmid-located integron in Pseudomonas aeruginosa clinical isolates from Spain.
Topics: Amikacin; Aminoglycosides; Anti-Bacterial Agents; beta-Lactamases; Cefepime; Cephalosporins; Clavulanic Acid; Gentamicins; Humans; Imipenem; Integrons; Meropenem; Molecular Sequence Data; Penicillanic Acid; Piperacillin; Plasmids; Pseudomonas aeruginosa; Pseudomonas Infections; Spain; Tazobactam; Thienamycins | 2009 |
Antibiotic utilization and Pseudomonas aeruginosa resistance in intensive care units.
Topics: Amikacin; Anti-Bacterial Agents; Cefoperazone; Ceftazidime; Ciprofloxacin; Czech Republic; Drug Resistance, Multiple, Bacterial; Gentamicins; Intensive Care Units; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Pseudomonas aeruginosa; Sulbactam; Tazobactam | 2011 |
First identification of blaIMI-1 in an Enterobacter cloacae clinical isolate from France.
Topics: Adult; Amikacin; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Enterobacter cloacae; Enterobacteriaceae Infections; France; Humans; Male; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Pneumonia, Ventilator-Associated; RNA, Ribosomal, 16S; Sequence Analysis, DNA; Tazobactam | 2012 |
Role of efflux pumps: MexAB-OprM and MexXY(-OprA), AmpC cephalosporinase and OprD porin in non-metallo-β-lactamase producing Pseudomonas aeruginosa isolated from cystic fibrosis and burn patients.
Topics: Amikacin; Anti-Bacterial Agents; Bacterial Outer Membrane Proteins; Bacterial Proteins; beta-Lactamases; Burns; Cephalosporinase; Cystic Fibrosis; Drug Resistance, Multiple, Bacterial; Escherichia coli Proteins; Gene Expression Regulation, Bacterial; Humans; Membrane Transport Proteins; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Porins; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2014 |
An Immunocompromised Child with Bloodstream Infection Caused by Two Escherichia coli Strains, One Harboring NDM-5 and the Other Harboring OXA-48-Like Carbapenemase.
Topics: Adolescent; Amikacin; Anti-Bacterial Agents; Aztreonam; Bacterial Proteins; beta-Lactamases; beta-Lactams; Ciprofloxacin; Ertapenem; Escherichia coli; Female; Gentamicins; Humans; Immunocompromised Host; Meropenem; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Tazobactam; Thienamycins; Tobramycin | 2016 |
Pneumocephalus in Child Following Bilateral Otomastoiditis and Nasal Septum Infection.
Topics: Amikacin; Anti-Bacterial Agents; Humans; Infant; Male; Mastoiditis; Nasal Septum; Otitis Media; Penicillanic Acid; Piperacillin; Pneumocephalus; Pseudomonas Infections; Subdural Effusion; Tazobactam; Tomography, X-Ray Computed; Treatment Outcome | 2016 |
Multidrug-Resistant Pseudomonas aeruginosa Infection in a Child with Cystic Fibrosis.
Topics: Adolescent; Amikacin; Anti-Bacterial Agents; beta-Lactams; Ciprofloxacin; Cystic Fibrosis; Drug Hypersensitivity; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Female; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2016 |
A change for the antibacterial treatment policy to decrease carbapenem consumption at a haematopoietic stem cell transplantation centre.
Topics: Amikacin; Anti-Bacterial Agents; Carbapenems; Cross Infection; Febrile Neutropenia; Guidelines as Topic; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Penicillanic Acid; Piperacillin; Retrospective Studies; Tazobactam; Teicoplanin; Tertiary Care Centers; Treatment Outcome; Turkey; Vancomycin | 2017 |
In vitro activity of ceftolozane/tazobactam in combination with other classes of antibacterial agents.
Topics: Amikacin; Aztreonam; Cephalosporins; Drug Antagonism; Drug Synergism; Drug Therapy, Combination; Gram-Negative Bacteria; Humans; Meropenem; Microbial Sensitivity Tests; Tazobactam; Tigecycline | 2017 |
Antibiotics susceptibility patterns of uropathogenic E. coli with special reference to fluoroquinolones in different age and gender groups.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amikacin; Anti-Bacterial Agents; Cefoperazone; Child; Child, Preschool; Cross-Sectional Studies; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Female; Fluoroquinolones; Humans; Imipenem; Infant; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Sulbactam; Tazobactam; Urinary Tract Infections; Young Adult | 2017 |
Antimicrobial Activity of Ceftolozane-Tazobactam Tested Against Enterobacteriaceae and Pseudomonas aeruginosa with Various Resistance Patterns Isolated in U.S. Hospitals (2013-2016) as Part of the Surveillance Program: Program to Assess Ceftolozane-Tazoba
Topics: Amikacin; Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Hospitals; Humans; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Thienamycins | 2018 |
Antibacterial effect of ceftolozane/tazobactam in combination with amikacin against aerobic Gram-negative bacilli studied in an in vitro pharmacokinetic model of infection.
Topics: Amikacin; Anti-Bacterial Agents; Bacterial Load; beta-Lactamase Inhibitors; Cephalosporins; Drug Therapy, Combination; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Meropenem; Microbial Sensitivity Tests; Microbial Viability; Models, Theoretical; Tazobactam | 2018 |
Antimicrobial activity of ceftolozane-tazobactam against multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa clinical isolates from a Spanish hospital.
Topics: Adult; Aged; Aged, 80 and over; Amikacin; Anti-Bacterial Agents; beta-Lactamases; Cephalosporins; Colistin; Cross Infection; Drug Resistance, Multiple, Bacterial; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Spain; Tazobactam | 2019 |
Synergistic Effect of Tazobactam on Amikacin MIC in Acinetobacter baumannii Isolated from Burn Patients in Tehran, Iran.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Amikacin; Anti-Bacterial Agents; Burns; Drug Resistance, Multiple, Bacterial; Drug Synergism; Genes, Bacterial; Humans; Iran; Microbial Sensitivity Tests; Tazobactam | 2020 |
In vitro activity of ceftolozane/tazobactam alone and in combination with amikacin against MDR/XDR Pseudomonas aeruginosa isolates from Greece.
Topics: Amikacin; Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Greece; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2020 |
Antimicrobial Activity of Ceftazidime-Avibactam, Ceftolozane-Tazobactam and Comparators Tested Against
Topics: Amikacin; Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactam Resistance; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Multiple, Bacterial; Humans; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Phenotype; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Tazobactam; United States; Whole Genome Sequencing | 2021 |
Antibiotic allergy in children with cystic fibrosis: A retrospective case-control study.
Topics: Amikacin; Anti-Bacterial Agents; Azithromycin; Case-Control Studies; Ceftazidime; Child; Ciprofloxacin; Cystic Fibrosis; Drug Hypersensitivity; Humans; Levofloxacin; Meropenem; Piperacillin; Retrospective Studies; Tazobactam; Trimethoprim, Sulfamethoxazole Drug Combination | 2022 |
Genotypic resistance determined by whole genome sequencing versus phenotypic resistance in 234 Escherichia coli isolates.
Topics: Amikacin; Amoxicillin; Anti-Bacterial Agents; Cefepime; Cefotaxime; Ceftazidime; Ciprofloxacin; Clavulanic Acid; Escherichia coli; Escherichia coli Infections; Genotype; Gentamicins; Humans; Meropenem; Microbial Sensitivity Tests; Phenotype; Piperacillin; Retrospective Studies; Tazobactam; Tobramycin; Whole Genome Sequencing | 2023 |
In-vitro activity of ceftolozane/tazobactam against Pseudomonas aeruginosa collected in the Study for Monitoring Antimicrobial Resistance Trends (SMART) between 2016 and 2019 in China.
Topics: Amikacin; Anti-Bacterial Agents; beta-Lactamase Inhibitors; Cephalosporins; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2023 |
Characteristics of and antibiotic resistance in urinary tract pathogens isolated from patients with upper urinary tract stones.
Topics: Aged; Amikacin; Anti-Bacterial Agents; Cefoperazone; Drug Resistance, Bacterial; Drug Resistance, Microbial; Escherichia coli; Female; Humans; Male; Microbial Sensitivity Tests; Piperacillin; Sulbactam; Tazobactam; Urinary Calculi; Urinary Tract; Urinary Tract Infections | 2023 |
In vitro activity of imipenem/relebactam against non-Morganellaceae Enterobacterales and Pseudomonas aeruginosa in the Asia-Pacific region: SMART 2017-2020.
Topics: Amikacin; Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamases; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Piperacillin; Pseudomonas aeruginosa; Tazobactam; Thailand | 2023 |